CSL Ltd Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 8/22/2026)
| Balance Sheet | Total Assets | 6,518,016,272.76 | ROE | 43.98 % |
| Balance Sheet | Total Equity | 2,866,524,602.87 | ROA | -7.70 % |
| Cashflow | Capital Expenditures | -648,885,797.00 | P/FCF | 21.56 |
| Cashflow | Free Cash Flow | 2,878,802,920.00 | – | – |
| Cashflow | Operating Cash Flow | 3,527,688,717.00 | P/CF | 17.60 |
| Income | Earnings per Share (diluted) | -0.26 | Div. Yield | 2.30 % |
| Income | Net Income | -501,844,440.14 | P/E | -123.85 |
| Income | Shares Outstanding | 1,927,920,000.00 | P/B | 21.66 |
| Income | Total Revenue | 3,054,654,397.52 | P/S | 20.32 |
Ratios calculated on: 10/14/2026
Company Description
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.csl.com.au
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more